News
Public · Published
Guggenheim maintains Regeneron Pharmaceuticals at Buy, raises price target to $1100 from $1030
Guggenheim kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1100 from $1030, a 6.8% increase. The new target implies 18.5% upside from the October 30 closing price of $927.89.
Published:
Updated:
What happened
Guggenheim kept its Buy rating on Regeneron Pharmaceuticals and raised its price target to $1100 from $1030, a 6.8% increase. The new target implies 18.5% upside from the October 30 closing price of $927.89.
Confirmed
Global impact / market context
A higher price target signals that Guggenheim sees more potential value in Regeneron shares, but it is an analyst estimate, not a guaranteed return. If investors act on the more favorable view, demand for the shares could rise; the article gives no evidence of an actual market reaction.
Analyst inference
Recent analyst views are mixed: the five listed targets range from $875 to $1175, while Guggenheim’s new $1100 target sits within that spread. This shows that analysts do not share one valuation view; the article provides no company operating results or explanation for the differing targets.
Analyst inference
What to watch
- Compare future analyst ratings and price targets with Guggenheim’s $1100 estimate to see whether professional views converge or continue to differ. Analyst inference
- Check whether Regeneron reports business results or guidance that explains a change in expected value; no such operating details are included here. Analyst inference
- The supplied article lists targets of $875 to $1175 across five recent notes and reports Guggenheim’s Buy rating and revised target. Confirmed
Evidence
- Original source link unavailable